{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T14:34:35Z","timestamp":1720362875925},"reference-count":75,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,12,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia, and myelofibrosis (MF) (both primary and secondary), are recognized for their burdensome symptom profiles, life-threatening complications, and risk of progression to acute leukemia. Recent advancements in our ability to diagnose and prognosticate these clonal malignancies have paralleled the development of MPN-targeted therapies that have had a significant impact on disease burden and quality of life. Ruxolitinib has shown success in alleviating the symptomatic burden, reducing splenomegaly and improving quality of life in patients with MF. The role and clinical expectations of JAK2 inhibition continues to expand to a variety of investigational arenas. Clinical trials for patients with MF focus on new JAK inhibitors with potentially less myelosuppression (pacritinib) or even activity for anemia (momelotinib). Further efforts focus on combination trials (including a JAK inhibitor base) or targeting new pathways (ie, telomerase). Similarly, therapy for PV continues to evolve with phase 3 trials investigating optimal frontline therapy (hydroxyurea or IFN) and second-line therapy for hydroxyurea-refractory or intolerant PV with JAK inhibitors. In this chapter, we review the evolving data and role of JAK inhibition (alone or in combination) in the management of patients with MPNs.<\/jats:p>","DOI":"10.1182\/asheducation-2014.1.277","type":"journal-article","created":{"date-parts":[[2014,11,24]],"date-time":"2014-11-24T18:39:03Z","timestamp":1416854343000},"page":"277-286","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Therapy for myeloproliferative neoplasms: when, which agent, and how?"],"prefix":"10.1182","volume":"2014","author":[{"given":"Holly L.","family":"Geyer","sequence":"first","affiliation":[{"name":"Division of Hospital Internal Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"1","key":"2019111702471893500_B1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"2019111702471893500_B2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111702471893500_B3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"5","key":"2019111702471893500_B4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111702471893500_B5","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"2019111702471893500_B6","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3324\/haematol.12011","article-title":"JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis","volume":"92","author":"Martinez-Aviles","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"2019111702471893500_B7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1182\/blood-2008-01-135897","article-title":"Characteristics and clinical correlates of MPL 515W>L\/K mutation in essential thrombocythemia","volume":"112","author":"Vannucchi","year":"2008","journal-title":"Blood"},{"issue":"10","key":"2019111702471893500_B8","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111702471893500_B9","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"issue":"25","key":"2019111702471893500_B10","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111702471893500_B11","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111702471893500_B12","article-title":"CALR mutation is a strong independent favorable prognostic variable in primary myelofibrosis","author":"Guglielmelli"},{"issue":"7","key":"2019111702471893500_B13","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"2019111702471893500_B14","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"10","key":"2019111702471893500_B15","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"2019111702471893500_B16","article-title":"Clinical charecteristics in myeloproliferative neoplasm with calreticulin mutations","author":"Kr\u00e4hling"},{"key":"2019111702471893500_B17","article-title":"Clinical and molecular response to inerferon alpha therapy in essential thrombocythemia patients with CALR mutations","author":"Verger"},{"key":"2019111702471893500_B18","article-title":"Outcome of JAK2\/MPL\/CALR triple negative patients with myelofibrosis after allogeneic stem cell transplantation","author":"Panagiota"},{"issue":"1","key":"2019111702471893500_B19","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"2019111702471893500_B20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","journal-title":"Blood"},{"issue":"33","key":"2019111702471893500_B21","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111702471893500_B22","first-page":"4067","article-title":"Myeloproliferative (MPN) symptom burden response thresholds: assessment of MPN-SAF TSS quartiles as potential markers of symptom response. [abstract]","volume":"122","author":"Emanuel","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"4","key":"2019111702471893500_B23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"2019111702471893500_B24","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"issue":"5","key":"2019111702471893500_B25","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL-myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111702471893500_B26","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1182\/blood-2012-01-403279","article-title":"A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment","volume":"120","author":"Passamonti","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2019111702471893500_B27","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"13","key":"2019111702471893500_B28","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"issue":"9","key":"2019111702471893500_B29","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"issue":"24","key":"2019111702471893500_B30","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood-2013-09-527903","article-title":"Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients","volume":"123","author":"Geyer","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111702471893500_B31","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111702471893500_B32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1056\/NEJMoa035572","article-title":"Efficacy and safety of low-dose aspirin in polycythemia vera","volume":"350","author":"Landolfi","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111702471893500_B33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111702471893500_B34","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111702471893500_B35","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2012-07-443770","article-title":"Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial","volume":"121","author":"Gisslinger","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111702471893500_B36","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-07-442012","article-title":"Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a","volume":"122","author":"Quintas-Cardama","year":"2013","journal-title":"Blood"},{"issue":"29","key":"2019111702471893500_B37","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1200\/JCO.2011.36.0792","article-title":"Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980","volume":"29","author":"Kiladjian","year":"2011","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111702471893500_B38","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2002-09-2928","article-title":"A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia","volume":"101","author":"Mesa","year":"2003","journal-title":"Blood"},{"issue":"22","key":"2019111702471893500_B39","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1182\/blood-2010-05-287417","article-title":"Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903","volume":"116","author":"Mesa","year":"2010","journal-title":"Blood"},{"issue":"21","key":"2019111702471893500_B40","first-page":"394","article-title":"Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofibrosis with RBC-transfusion-dependence [abstract]","volume":"122","author":"Tefferi","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"2019111702471893500_B41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111702471893500_B42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","article-title":"Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic","volume":"107","author":"Mesa","year":"2006","journal-title":"Cancer"},{"issue":"9","key":"2019111702471893500_B43","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"2019111702471893500_B44","article-title":"Results from a 3.5 year update of COMFORT-II, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of myelofibrosis","author":"Harrison"},{"issue":"21","key":"2019111702471893500_B45","first-page":"1733","article-title":"Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I [abstract]","volume":"120","author":"Mesa","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111702471893500_B46","first-page":"2826","article-title":"Response to ruxolitinib in patients with intermediate-1, intermediate-2 and high-risk myelofibrosis:interim results of the UK Robust Trial [abstract]","volume":"122","author":"Harrison","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"4","key":"2019111702471893500_B47","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/cncr.28441","article-title":"A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea","volume":"120","author":"Verstovsek","year":"2014","journal-title":"Cancer"},{"key":"2019111702471893500_B48","article-title":"Results of a prospective, randomized, open-label Phase III study of ruxolitinib in polycythemia vera patients resistant to or intolerant of hydroxyurea: the RESPONSE trial","author":"Vannucchi"},{"issue":"6","key":"2019111702471893500_B49","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/leu.2013.71","article-title":"Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"21","key":"2019111702471893500_B50","first-page":"395","article-title":"Pacritinib, a dual JAK2\/FLT3 inhibitor: an integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts \u2264100,000\/\u03bcl [abstract]","volume":"122","author":"Verstovsek","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111702471893500_B51","first-page":"393","article-title":"Results of a randomized, double-blind, placebo-controlled phase III study (JAKARTA) of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis (MF) [abstract]","volume":"122","author":"Pardanini","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"5573","key":"2019111702471893500_B52","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"issue":"10","key":"2019111702471893500_B53","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Burchert","year":"2005","journal-title":"Leukemia"},{"issue":"11","key":"2019111702471893500_B54","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/jcmm.12156","article-title":"Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors","volume":"17","author":"Choong","year":"2013","journal-title":"J Cell Mol Med"},{"issue":"3","key":"2019111702471893500_B55","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1097-2765(02)00636-6","article-title":"Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control","volume":"10","author":"Loewith","year":"2002","journal-title":"Mol Cell"},{"issue":"8","key":"2019111702471893500_B56","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood-2011-01-330563","article-title":"Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1\/2 study in patients with myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2019111702471893500_B57","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.exphem.2012.04.007","article-title":"The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells","volume":"40","author":"Amaru Calzada","year":"2012","journal-title":"Exp Hematol"},{"issue":"23","key":"2019111702471893500_B58","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1182\/blood-2011-12-397976","article-title":"Non-cell-autonomous hedgehog signaling promotes murine B lymphopoiesis from hematopoietic progenitors","volume":"119","author":"Cooper","year":"2012","journal-title":"Blood"},{"key":"2019111702471893500_B59","doi-asserted-by":"crossref","article-title":"Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: stage 1 results","author":"Verstovsek","DOI":"10.1182\/blood.V124.21.713.713"},{"issue":"21","key":"2019111702471893500_B60","first-page":"179","article-title":"Imetelstat rapidly induces and maintains substantial hematologica and molecular responses in patients with essential thrombocythemia (ET) who are refractory or intolerant to prior therapy: preliminary phase II results [abstract]","volume":"120","author":"Baerlocher","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111702471893500_B61","first-page":"662","article-title":"Imetelstat, a telomerase inhibitor, induces morphologica and molecular remissions in myelofibrosis and recersal of bone marrow fibrosis [abstract]","volume":"120","author":"Tefferi","year":"2012","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111702471893500_B62","first-page":"306","article-title":"Ruxolitinib before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with myelofibrosis: a preliminary descriptive report of the JAK ALLO study, a phase II trial sponsored by Goelams-FIM in collaboration with the SFGMTC [abstract]","volume":"122","author":"Robin","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"21","key":"2019111702471893500_B63","first-page":"392","article-title":"Ruxolitinib as pretreatment before allogeneic stem cell transplantation for myelofibrosis [abstract]","volume":"122","author":"Kroger","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"9","key":"2019111702471893500_B64","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.leukres.2012.04.021","article-title":"Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase","volume":"36","author":"Cherington","year":"2012","journal-title":"Leuk Res"},{"issue":"4","key":"2019111702471893500_B65","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","article-title":"Thrombosis in primary myelofibrosis: incidence and risk factors","volume":"115","author":"Barbui","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2019111702471893500_B66","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3324\/haematol.2010.025064","article-title":"Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked","volume":"95","author":"Elliott","year":"2010","journal-title":"Haematologica"},{"issue":"3","key":"2019111702471893500_B67","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1200\/JCO.1990.8.3.556","article-title":"Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia","volume":"8","author":"Cortelazzo","year":"1990","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111702471893500_B68","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111702471893500_B69","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.amjmed.2004.06.032","article-title":"Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia","volume":"117","author":"Passamonti","year":"2004","journal-title":"Am J Med"},{"issue":"23","key":"2019111702471893500_B70","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111702471893500_B71","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2141.2010.08275.x","article-title":"Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence","volume":"150","author":"Passamonti","year":"2010","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111702471893500_B72","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/bjh.12117","article-title":"Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients","volume":"160","author":"Bonicelli","year":"2013","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111702471893500_B73","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3109\/10428194.2013.784970","article-title":"Significance of cytogenetic abnormalities in patients with polycythemia vera","volume":"54","author":"Sever","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2019111702471893500_B74","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1002\/cncr.23505","article-title":"Risk factors for leukemic transformation in patients with primary myelofibrosis","volume":"112","author":"Huang","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"2019111702471893500_B75","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/277\/1249870\/bep00114000277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2014\/1\/277\/1249870\/bep00114000277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T07:47:36Z","timestamp":1573976856000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2014\/1\/277\/20451\/Therapy-for-myeloproliferative-neoplasms-when"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2014.1.277","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}